Skip to content

In the BioHarmony Drug Report Database


Zokinvy (lonafarnib) is a small molecule pharmaceutical. Lonafarnib was first approved as Zokinvy on 2020-11-20. It is known to target GTPase NRas, GTPase HRas, GTPase KRas, and protein farnesyltransferase subunit beta. Zokinvy's patent is valid until 2024-07-26 (FDA).
Trade Name Zokinvy
Common Name Lonafarnib
Drug Class Farnesyl transferase inhibitor
Get full access now